About SanionaSaniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Upsher-Smith Laboratories, Inc., Productos Medix, S.A and Luc Therapeutics, Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 4,500 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION.
Founder and CEO: Jørgen Drejer
Founder and CFO: Thomas Feldthus
Founder and CSO: Palle Christophersen
48 articles with Saniona
Saniona's Partner, Productos Medix, S.A de S.V, Initiates Phase III Study For Tesofensine In Obesity
Saniona's Partner, Luc Therapeutics, Nominates Clinical Candidate And Initiates Preclinical Development In Joint Ataxia Program